Study #2018-0486
A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination with Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), in Patients with HER2-Positive Metastatic Breast Cancer who have Progressed on Prior Trastuzumab and Pertuzuma
MD Anderson Study Status
Not Accepting
Treatment Agent
Vinorelbine, Trastuzumab, Avelumab, Utomilumab
Description
This research study is studying a combination of drugs as a possible treatment for breast cancer. The drugs involved in this study are: * Group A: Trastuzumab (Herceptin) + Vinorelbine (Navelbine) * Group B: Trastuzumab + Vinorelbine + Avelumab * Group C: Trastuzumab + Vinorelbine + Avelumab + Utomilumab (PF-05082566)
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Breast Cancer
Study phase:
Phase II
Physician name:
Rashmi Murthy
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-844-939-2381
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.